Director-General's Statement Under Section 98 of the Medicines A.
http://www.moh.govt.nz/moh.nsf/0/3711B8F68E771F8FCC257. Media Release 1 March 2006 Director-General's Statement Under Section 98 of the Medicines Act 1981
Director-General of Health Dr Karen Poutasi is today warning people against taking two herbal
products after testing revealed they contained undeclared prescription medicines for weight loss
Tests by the Ministry of Health Medicines Safety Authority (Medsafe) have shown that the herbal
weight loss product Li Da contains the prescription medicine sibutramine, which is prescribed for
overweight (obese) patients who have not been able to lose weight using a low calorie diet and
Sibutramine can cause increased blood pressure and heart rate and cannot safely be taken by a
range of people, including those with glaucoma, mental illness and severe liver or kidney
problems. It should not be used in combination with other medicines such as some
antidepressants and migraine treatments, Dr Poutasi says.
A second herbal product Nasutra, has been found to contain the prescription medicine Sildenafil,
which is prescribed for the treatment of erectile dysfunction.
Sildenafil is known to interfere with some heart medication and could be fatal to some individuals.
"Consumers should immediately stop taking these two products," Dr Poutasi says. "People who
have taken Li Da or Nasutra should seek medical advice from their doctor if they are: taking other
medicines; have felt unwell when taking the products; or if they have become unwell after they
The two products were discovered following routine testing, surveillance activities and through
Action is being taken with respect to the distributors of these products and further investigations
by Medsafe are underway into the importation and supply of the products.
"It is illegal to sell or supply prescription medicines without the purchaser having a prescription
from a registered medical practitioner. Distributors, importers and sellers are responsible for
ensuring the products they import or sell do not contain any undeclared prescription medicines,"
"It is also illegal for an individual to possess personal supplies of a prescription medicine without
first having obtained a medical practitioner's prescription for them."
"Consumers need to be cautious as there may be other herbal products at risk of containing
prescription medicines or toxic substances. There are many examples in the international literature
where ‘herbal’ products for the treatment of impotence or for weight loss have been found to
Further information and photos of the two products are available on the Medsafe website
Director-General's Statement Under Section 98 of the Medicines A.
http://www.moh.govt.nz/moh.nsf/0/3711B8F68E771F8FCC257. Background information
The products Li Da and Nasutra were investigated following information received by Medsafe and
through surveillance activities carried out at the border. Subsequent testing showed that Li Da
contained the prescription medicine sibutramine, and Nasutra contained the prescription medicine
As these products contain a prescription medicine and are clearly for a therapeutic use, they are
considered to be a medicines distributed without the consent of the Minister, in contravention of
the Medicines Act 1981. Before the Minister gives consent to the distribution of a medicine, its
quality, safety and efficacy must be assessed against and meet international guidelines. This
application process for approval has not occurred with either product.
Consequently, Medsafe has required known sellers of Li Da and Nasutra to immediately stop
supplying these products. Further investigations are underway into the importation and supply of
Why are these products a problem?
Li Da was investigated following complaints received by Medsafe about side effects of the product
and because border surveillance had indicated increased attempts to import the product. Testing
showed that it contained the prescription medicine sibutramine. Reductil is the only brand of
sibutramine approved for sale in New Zealand and is used for managing overweight (obese)
patients. Sibutramine can cause increased blood pressure and heart rate. Patients using
sibutramine must see their doctor for a check-up every two weeks during the first three months of
treatment in order to monitor the effects of use.
Additionally, sibutramine must not be given to certain persons (for example, those with glaucoma,
mental illness, severe liver or kidney problems) nor should it be used in combination with
medicines such as some antidepressants and migraine treatments. Li Da is labelled in Chinese
characters, information about it indicates that it is claimed to be a herbal product.
The product Nasutra contains the prescription medicine sildenafil. Viagra is the only brand of
sildenafil approved for sale in new Zealand and is used for managing erectile dysfunction.
Sildenafil is known to interfere with some heart medication and could be fatal to some individuals.
Nasutra is labelled as a herbal supplement and lists only herbal materials as ingredients.
It is a breach of the Medicines Act 1981 for so-called herbal products to contain undeclared
prescription medicines. There is a real potential for harm to occur when prescription medicines are
unknowingly used by consumers, particularly in the absence of medical supervision.
Is there information available for consumers about the active ingredient?
Sibutramine is the active ingredient in Reductil and Sildenafil is the active ingredient in Viagra.
Consumers seeking general information about sibutramine or sildenafil can access the Consumer
medication information about Reductil and Viagra on the Medsafe web site. Are these products being removed from the market?
Known distributors are being warned that these products cannot be sold. Medsafe believes that no
further supplies remain with these distributors.
Distributors, importers and sellers are responsible for ensuring products they import or sell that
are not approved medicines do not contain any prescription medicines.
Also, it is illegal to sell or supply prescription medicines without the purchaser having a
prescription from a registered medical practitioner.
Under the food and medicine legislation, sponsors/distributors/importers are required to list all
active ingredients on the packaging, and to include the strength of each active ingredient. If a consumer is taking Li Da or Nasutra what should they do?
Director-General's Statement Under Section 98 of the Medicines A.
http://www.moh.govt.nz/moh.nsf/0/3711B8F68E771F8FCC257.
Consumers are being warned to immediately stop taking these products.
Consumers should seek medical advice from their doctor:
if they are taking other medicinesif they felt unwell when taking Li Da or Nasutraif they become unwell after they stopped taking Li Da or Nasutra
How many people take these products in New Zealand?
There is no reliable information about how many people have taken these products. How were these illegal products being sold?
Li Da appears to have been imported by individuals either for personal use or for supply to other
individuals. Some traders appear also to have imported for retail supply. Nasutra was being sold
Can these products still be sold?
No. Medsafe has required the distributors of these products to immediately cease supplying it.
Stocks have been seized from known sellers. General warning for consumers about any products making therapeutic claims
Medsafe warns consumers that products making therapeutic claims being sold through websites
may not be legal in New Zealand. All products for which a therapeutic benefit is being claimed
must first be ‘approved’ by the Minister of Health before they can be marketed.
Consumers should also be alert to complementary healthcare products that appear to be of poor
quality, cause side effects, or appear to be unusually effective or are available from unusual
Any concerns should be reported to Medsafe. See the Medsafe website for contact details.
Adverse reactions to these products or to any herbal product should be reported to the Centre for
Adverse Reactions Monitoring http://carm.otago.ac.nz/. This is a very important means of picking
up issues with herbal medicines at an early stage. Important advice to traders
Medicines are products sold or supplied principally for a therapeutic purpose. Selling, distributing
or advertising the availability of a medicine which has not been given a consent or provisional
consent by the Minister is in breach of section 20 of the Medicines Act 1981.
On conviction, the maximum penalty for an individual who sells a medicine without first having it
registered through the regulatory process administered by Medsafe is $20,000 or up to 6 months
Unless a product is an approved medicine, sellers must ensure that claims of a therapeutic
purpose are not made for products they advertise or sell AND they must ensure that their
products do not contain scheduled medicines. It may, for instance, be prudent to test products
The Ministry of Health advises traders that it takes breaches of the medicines legislation very
seriously where patient / consumer safety is put at risk.
Related information
Privacy | Copyright 2006 | Disclaimer | About Us | Access Keys | Feedback | Contact Us |Employment | www.govt.nz
Director-General's Statement Under Section 98 of the Medicines A.
http://www.moh.govt.nz/moh.nsf/0/3711B8F68E771F8FCC257.
Trade preferences and developing countries: Dealing with inequities Small developing economies and the multilateral Dr.Richard L.Bernal , Small developing economies are often constrained in participating in the negotiation and regulation of multilateral trading rules due to severe cost and resource limitations. This article argues that, despite the costs and difficulties, small st
Takeda leads the way on skills Founded in 1781 and headquartered in Osaka, Japan, Takeda Cambridge showed an early interest in working Takeda is a research-based global pharmaceutical with Cogent to develop a training framework for SMEs company. Worldwide, Takeda markets a number of and in the new Higher Apprenticeship in Life Sciences blockbuster drugs discovered through its internal
Director-General's Statement Under Section 98 of the Medicines A.